A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Public ClinicalTrials.gov record NCT06226545. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Study identification
- NCT ID
- NCT06226545
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Lassen Therapeutics Inc.
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Interventions
- LASN01 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 4, 2024
- Primary completion
- Apr 21, 2025
- Completion
- Apr 21, 2025
- Last update posted
- Mar 8, 2026
2024 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 111 | Beverly Hills | California | 90210 | — |
| Site 105 | Palo Alto | California | 94303 | — |
| Site 101 | San Diego | California | 92093 | — |
| Site 103 | Miami | Florida | 33136 | — |
| Site 108 | Livonia | Michigan | 48152 | — |
| Site 112 | Las Vegas | Nevada | 89144 | — |
| Site 110 | Wilmington | North Carolina | 28403 | — |
| Site 106 | Houston | Texas | 77030 | — |
| Site 104 | Houston | Texas | 77401 | — |
| Site 109 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06226545, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06226545 live on ClinicalTrials.gov.